Government is heavily involved in funding bioscience/medicine knowledge advances.
Government is the primary payer for medicine delivery to patients.
It is widely accepted that there is a market failure in the translation between these extremities of the medicine discovery process.
Governments should vigorously support social enterprise approaches to bridging the gap between medical knowledge and new medicine discovery.
INMedD will provide a significant contribution to the UK’s biopharma research base and thereby sustain this part of the knowledge economy by recycling the skill set being shed from pharma companies and by providing a multidisciplinary training ground for the next generation of drug hunters. Benefits to global health will be created at the same time as contributions to local wealth.
INMedD is a social enterprise providing one component in a toolbox to extract full social and commercial economic benefit from the large government investment in academic chemistry and bioscience. Fully commercial business models fail to effectively translate excellent bioscience advances into medicines for patients. Sustainable success will be achieved by taking projects to a position where sufficient risk has been removed to allow investment for onward development.
The future global demand for new medicines will grow dramatically as the population ages and under-developed economies ‘emerge’. The very large investments in biotech and pharma companies have recently resulted in only about 20 new medicines reaching the market each year.
UK is predicted to fall from 6th in 2003 to 10th in 2013 in the league table of pharmaceutical markets. Pharmaceutical companies have reduced and will continue to reduce their research investment in the UK.
There is an imminent threat to small molecule drug discovery excellence in the UK which has an extensive history of success.
INMedD will take advantage of the current opportunity to hire excellent industry-experienced people. INMedD plans to employ a minimum of 50 scientists focused on the translation of biocience knowledge to valuable medicines.
INMedD complements the excellent work in the UK of Wellcome Trust, MRCT and CRT in bridging the early stage drug discovery gap.
A key objective, in addition to discovering the medicines themselves, is to provide ‘quaternary’ education in small molecule new medicine discovery for the next generation of drug hunters through hosting secondees from other organizations.
Universities find it difficult to create interdisciplinary expertise. The academic culture is one of individual intradiscipline excellence rather than team excellence. INMedD provides a focal point to facilitate the integration of opportunities created by academic bioscience with the processes and commercial discipline of pharmaceutical companies.
New medicine discovery is critical for society. For the foreseeable future there will be growing demand as populations age and become more knowledgeable about controlling disease.
Investment in Pharma R&D in the UK is falling. Recruitment is lower. Renewal of the cohort skilled in interdisciplinary science will decrease. Replacement of this skilled cohort in 10 years time will not be possible.